Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus
Status:
Terminated
Trial end date:
2021-05-31
Target enrollment:
Participant gender:
Summary
Randomized, double blind, placebo-controlled clinical trial examining the efficacy and safety
of mifepristone 600 mg daily in male subjects with type 2 diabetes mellitus, not associated
with Cushing's syndrome